Beating Cancer Cells at Their Own Game

For many patients with cancer, treatment resistance develops, leaving cancerous cells to continue to proliferate. Viewing the capability of cancer cells to develop resistance to drugs as a type of evolutionary game, researchers at the Cleveland Clinic developed a game assay using a model of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) cells to measure and explain the interactions between drug-sensitive and drug-resistant cancer cells.  "Rather than searching ...

In Melanoma, Smoking Impacts Antitumor Immune Response

The immune system's response to melanoma both improves survival for untreated patients and predicts a patient's response to immune checkpoint blockade therapy. A British study has now identified several genetic factors that can be used to predict a patient's immune response to melanoma. The study has also identified a significant environmental cause of lowered antitumor immunity: cigarette smoking. For the study, published in Cancer Research , investigators used a bioinformatic analysis of 703 t...

DNA Damage Repair Inhibitors Fight Small Cell Lung Cancer

Patients with small cell lung cancer (SCLC) often do not respond to immune checkpoint blockade therapy alone. However, researchers at the University of Texas MD Anderson Cancer Center now report that a combination of immune checkpoint blockade therapy and targeted therapies blocking DNA damage repair significantly shrinks tumors in mouse models of SCLC. "While the use of immunotherapy has revolutionized the way we treat lung cancer, we find that small cell lung cancers can escape the immune syst...

Advanced Renal-Cell Carcinoma: Potential First-Line Treatment

​ A phase 3 clinical trial has found that in previously untreated patients with advanced renal-cell carcinoma (RCC), avelumab plus axitinib improves progression-free survival and objective response compared with sunitinib. Sunitinib is an antiangiogenic drug, meaning that it prevents tumors from growing their own blood vessels. It is considered standard of care as a first-line therapy for patients with advanced RCC. However, many patients either have inherent resistance to antiangiogenic drugs o...

Glyphosate-Based Herbicides Linked to Non-Hodgkin Lymphoma

Researchers report that glyphosate, the herbicide commonly found in Roundup® (Monsanto Technology, LLC), which is used as a pesticide on produce, significantly increases the risk of developing non-Hodgkin lymphoma (NHL) in humans. "Our analysis focused on providing the best possible answer to the question of whether or not glyphosate is carcinogenic," remarked the senior author of the paper, Lianne Sheppard, PhD, Professor of Environmental and Occupational Health Sciences and Biostatistics at th...

© Copyright 2019 i3 Health. All rights reserved.